Recent advances in the Prevention and Treatment of Chemotherapy–induced Cardiotoxicity

Main Article Content

Hanieh Kazemian
Hassan Mehrad-Majd


The current study aimed to overview recent advances in preventing and treating chemotherapy-induced cardiotoxicity. Chemotherapy is widely used in cancer treatment, however, it can have adverse effects on the heart, leading to the development of risk factors, such as hypertension, obesity, dyslipidemia, and metabolic syndrome. Anthracycline compounds are the most commonly used chemotherapy agents and are associated with an increased risk of developing anthracycline-induced cardiotoxicity (AIC). The precise mechanisms underlying AIC remain a subject of debate, but evidence suggests that the primary causes are the generation of reactive oxygen species (ROS) and subsequent oxidative stress. Several risk factors have been linked to the development of AIC, including cumulative dose, pre-existing cardiac disease, age, gender, and cardiac risk factors. Genetic susceptibility may also play a role as a potential risk factor for AIC. In order to protect cardiac function, various strategies have been explored, such as developing less-toxic derivatives of anthracyclines, determining safer cumulative anthracycline doses, and identifying new cardioprotective agents. Prophylactic treatment with cardioprotective agents is the best approach for high-risk patients. This article reviewed the present strategies for protecting cancer patients from AIC based on effective cardioprotective drugs along with the balance between their benefits and potential adverse effects.

Article Details

How to Cite
Kazemian, H., & Mehrad-Majd, H. (2023). Recent advances in the Prevention and Treatment of Chemotherapy–induced Cardiotoxicity. Research in Biotechnology and Environmental Science, 2(2), 24–29.
Reveiw Article


Cardinale D, Bacchiani G, Beggiato M, Colombo A, and Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol. 2013; 40(2):186-198. DOI:

Ky B, Vejpongsa P, Yeh ET, Force T, and Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013; 113(6): 754-764. DOI:

Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13(1): 1-10. DOI:

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010; 10: 337. DOI:

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3): 213-220. DOI:

Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7): 727-741. DOI:

Force T, and Wang Y. Mechanism-based engineering against anthracycline cardiotoxicity. Circulation. 2013; 128(2): 98-100. DOI:

Kocik M, Zimovjanova M, Petruzelka L, Kodydkova J, Vavrova L, and Zak A. Oxidative stress after anthracycline therapy in patients with solid tumors. Cas Lek Ces. 2012; 151(10): 463-467. Available at:

Chung WB, Yi JE, Jin JY, Choi YS, Park CS, Park WC, et al. Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer. 2013; 16(2): 178-183. DOI:

Vejpongsa P, and Yeh ET. Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J Am Coll Cardiol. 2014; 64(9): 938-945. DOI:

Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, and Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep. 1981; 65(11-12): 1093-1097. PubMed PMID: 7296554

Geisberg CA, and Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12(6): 404-410. DOI:

Horenstein MS, Vander Heide RS, and L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000; 71(1-2): 436-44. DOI:

Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J Mol Cell Cardiol. 2006; 41(3): 389-405. DOI:

Wang L, Ma W, Markovich R, Chen JW, and Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998; 83(5): 516-522. DOI:

Childs AC, Phaneuf SL, Dirks AJ, Phillips T, and Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res. 2002; 62(16): 4592-4598.

Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011; 7(4): 214-220. DOI:

Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56(2): 185-229. DOI:

Liu J, Mao W, Ding B, and Liang CS. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physio Heart Circ Physio. 2008; 295(5): H1956-H1965. DOI:

Tewey KM, Rowe TC, Yang L, Halligan BD, and Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984; 226(4673): 466-468. DOI:

Vejpongsa P, and Yeh ET. Topoisomerase 2beta: A promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014; 95(1): 45-52. DOI:

Kersting G, Tzvetkov MV, Huse K, Kulle B, Hafner V, Brockmoller J, et al. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(1): 21-30. DOI:

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11): 1639-1642. DOI:

Buzdar AU, Marcus C, Smith TL, and Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985; 55(12):

-2765. DOI:;2-P

Yeh ET, and Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management.

J Am Coll Cardiol. 2009; 53(24): 2231-2247. DOI:

Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat. 2007; 104(3): 341-349. DOI:

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91(5): 710-717. DOI:

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012; 30(13): 1422-1428. DOI:

Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ, et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016; 17(3): 231-240. DOI:

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015; 16(10): 1065-1076. DOI:

Reichwagen A, Ziepert M, Kreuz M, Godtel-Armbrust U, Rixecker T, Poeschel V, et al. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial

of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics. 2015; 16(4): 361-372. DOI:

Wang X, Sun CL, Quinones-Lombrana A, Singh P, Landier W, Hageman L, et al. CELF4 variant and anthracycline-related cardiomyopathy: A children’s oncology group genome-wide association study. J Clin Oncol. 2016; 34(8): 863-870. DOI:

Leong SL, Chaiyakunapruk N, and Lee SW. Candidate gene association studies of anthracycline-induced cardiotoxicity: A systematic review and meta-analysis. Sci Rep. 2017; 7(1): 39. DOI:

Storm G, van Hoesel QG, de Groot G, Kop W, Steerenberg PA, and Hillen FC. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Cancer Chemother Pharmacol. 1989; 24(6): 341-8. DOI:

Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982; 96(2): 133-139. DOI:

Waterhouse DN, Tardi PG, Mayer LD, and Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Saf. 2001; 24(12): 903-920. DOI:

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Card. 2011; 107(9): 1375-1380. DOI:

Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001; 141(6): 1007-1013. DOI:

Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000; 104(4): 158-163. DOI:

Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem. 2005; 51(8): 1405-1410. DOI:

Swain SM, Whaley FS, and Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003; 97(11): 2869-2879. DOI:

Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, and Hsu DT. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. Circulation. 2013; 128(17): 1927-1995. DOI:

Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23): 2474-2481. DOI:

Swain SM, and Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 2004; 130(1): 1-7. DOI:

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007; 25(5): 493-500. DOI:

Lyman GH, Lyman CH, and Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10(6): 427-437. DOI:

van Dalen EC, van der Pal HJ, Caron HN, and Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009; (4): CD005008. DOI:

Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients. Asian Pac J Cancer Prev. 2021; 22(9):2847. Doi: 10.31557/APJCP.2021.22.9.2847

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Gonçalves Brandão SM, Carvalho Rigaud VO, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. J Am Coll Cardiol. 2018; 71(20): 2281-2290. Available at:

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37(21): 1671-1680. DOI:

Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2019; 12(8): 815-824. Doi: 10.1080/17512433.2019.1637252

Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48(11): 2258-2262. Available at: 07.052

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi M, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55(3): 213-220. Available at: 10.1016/j.jacc.2009.03.095

Seicean S, Seicean A, Plana JC, Budd GT, and Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012; 60(23): 2384-2390. Available at: j.jacc.2012.07.067

DjoussÚ L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish consumption, omega-3 fatty acids and risk of heart failure: a

meta-analysis. Clinical nutrition. 2012; 31(6):846-53. Doi: 10.1016/j.clnu.2012.05.010

Shen S, Gong C, Jin K, Zhou L, Xiao Y, Ma L. Omega-3 fatty acid supplementation and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials. Frontiers in Nutrition. 2022; 3(9):20.